Google's ambitious health startup is teaming up with biotechnology drugmaker AbbVie in a $500 million joint venture that will try to develop new ways to treat cancer and other diseases such as Alzheimer's.
(Medical Xpress)—Ongoing research at the Methodist Cancer Center could reveal whether metastatic breast cancer patients with BRCA gene mutations are particularly responsive to a drug regimen that includes Veliparib, an ...
(HealthDay)—Many pre-term babies suffer recurrent episodes of wheezing. Now, researchers say a common infection is a likely culprit and they may be able to prevent the breathing problems.
(HealthDay)—Humira (adalimumab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe ulcerative colitis in adults, the agency said Friday.
Abbott Laboratories said Monday that its experimental hepatitis C drug regimen cured 99 percent of patients in a midstage study with the most common and hardest-to-treat type of the disease.
In HIV-plagued sub-Saharan Africa, it can take up to three months for mothers to learn whether their babies have been infected by the deadly virus, delaying what could be life-sustaining treatment.
(HealthDay)—Combination treatment with fenofibrate and simvastatin (FENO-S) significantly reduces postprandial (PP) triglyceride (TG) levels compared with simvastatin alone in all subjects, regardless of ...
The Food and Drug Administration has approved Abbott Laboratories' ESA test for Chagas disease, which could be a useful tool in protecting the nation's blood supply from contamination.
(HealthDay)—For patients with moderate-to-severe hidradenitis suppurativa (HS), a chronic skin disease characterized by painful abscesses, nodules, and draining fistulas in the axilla and groin, treatment ...
Abbott Laboratories is recalling its FreeStyle InsuLinx Blood Glucose Meters after finding that they display and store incorrect test results for dangerously high blood sugar levels.
Abbott Laboratories is closing one of its manufacturing plants in the Puerto Rico town of Barceloneta next year, delivering another blow to the U.S. territory's once-thriving pharmaceutical sector, officials said Thursday.
U.S. drugmaker AbbVie has boosted its offer for Shire by 11 percent to about $51.3 billion, hoping it will be enough to pique the interest of its British counterpart.